Q-omics provides the consensus-scored GPAT2 profile across patient tissues and cancer cell-line models. GPAT2 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, GPAT2 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, GPAT2 RNA expression shows 11,473 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, KIRC, and TGCT as cancer lineages where GPAT2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GPAT2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GPAT2 survival associations across molecular data types. GPAT2 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GPAT2 RNA expression–survival associations across cancer types. High GPAT2 expression shows unfavorable associations in KIRP, COAD, LGG and LAML, but favorable associations in HNSC and OV. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for GPAT2 RNA expression.
This table summarizes GPAT2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for GPAT2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GPAT2 shows lower tumor expression in BRCA, COAD, KICH and UCEC and higher tumor expression in KIRC and LIHC. The KIRC box plot shows higher GPAT2 RNA expression in tumor versus normal tissue (log2 FC = +0.363, t-test p < 0.001).
This table shows molecular features associated with GPAT2 in patient tissues and cancer cell lines. In patient samples, GPAT2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, GPAT2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LARGE_INTESTINE.
